AgomAb Therapeutics NV has disclosed several stock transactions involving David R. Epstein, a director at the company. This development is significant as it indicates Epstein's growing confidence in AgomAb's future prospects, especially within the biological products sector.

Background

AgomAb Therapeutics NV operates in the biological products industry, specifically classified under SIC 2836, which includes biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker AGMB. Recent filings indicate an active engagement with shareholders, reflecting ongoing developments within the firm.

What the Filing Says

According to the recent filing dated November 6, 2026, Epstein reported acquiring 15,000 shares over three transactions on November 5, 2026. The shares were acquired at prices of $6.81, $6.91, and $6.98 per share. Following these transactions, Epstein's total ownership increased to 40,000 shares.

Impact

This increase in share ownership by Epstein may influence investor sentiment towards AgomAb Therapeutics. As a director, his actions can be seen as a positive signal about the company's direction and potential. Stakeholders and analysts in the biological products industry will likely monitor these developments closely, as they could impact market perceptions and competitive dynamics.

What's Next

The filing does not say what happens next.

Details of Transactions

The filing outlines that all transactions occurred on the same day, November 5, 2026, with Epstein acquiring a total of 15,000 shares through three separate purchases. The breakdown of these transactions is as follows:

  • 5,000 shares at $6.81 each
  • 5,000 shares at $6.91 each
  • 5,000 shares at $6.98 each

Following these transactions, Epstein's total share ownership rose to 40,000 shares, reflecting a direct ownership stake in AgomAb Therapeutics NV.

Ownership Structure

As noted in the filing, Epstein is classified as a director of AgomAb Therapeutics NV, but he is not an officer or a ten percent owner of the company. This distinction is important as it highlights his role in governance without a controlling interest.

Location and Contact Information

The filing provides Epstein's address as C/O AgomAb Therapeutics NV, located at Posthoflei 1/6, Antwerpen, Belgium, 2600. This non-US address indicates the international nature of the company's operations.

Additional Context

While the filing provides detailed information about the transactions and Epstein's ownership, it does not include any insights into the company's current financial performance, strategic initiatives, or any upcoming product launches that may be relevant to investors.